This article partakes in a number of recent attempts to map the reconfiguration of clinical work as part of the deployment of precision oncology. We focus on the platforms, in particular Molecular Tumor Boards, that act as a condition of possibility for implementing innovative experimental interventions, and which are part of the emergence, beyond the traditional confines of diagnosis, of a data “ecosystem” geared towards increasing patient access to drugs matched to their genomic profile. MTBs are a key component of this singularization process, and their activities are central to the looping mechanisms that connect the diagnosis of individual patients to the revision of diagnostic categories. These categories are no longer “merely” diagnostic but operate as predictive guides to therapy.

本文参与了许多近期的尝试，以绘制临床工作的重新配置图，以此作为部署精密肿瘤学的一部分。我们专注于平台，尤其是分子肿瘤板，这是实施创新性实验干预措施的可能条件，并且是超越传统诊断范围而出现的，旨在增加患者需求的数据“生态系统”的一部分获得与其基因组特征相匹配的药物。MTB是此单一化过程的关键组成部分，它们的活动对于将个体患者的诊断与诊断类别的修订联系起来的循环机制至关重要。这些类别不再只是“诊断”，而是作为治疗的预测指南。